Selected article for: "activation immune system response and acute respiratory syndrome"
Author: Wang, Xin; Sahu, Kamal Kant; Cerny, Jan
Title: Coagulopathy, endothelial dysfunction, thrombotic microangiopathy and complement activation: potential role of complement system inhibition in COVID-19
  • Cord-id: hsrhymu9
  • Document date: 2020_10_15
    • ID: hsrhymu9
    Snippet: Coronavirus disease-2019 (COVID-19) is a rapidly evolving health crisis caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 is a novel disease entity and we are in a learning phase with regards to the pathogenesis, disease manifestations, and therapeutics. In addition to the primary lung injury, many patients especially the ones with moderate to severe COVID-19 display evidence of endothelial damage, complement activation, which leads to a pro-coagulable state. W
    Document: Coronavirus disease-2019 (COVID-19) is a rapidly evolving health crisis caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 is a novel disease entity and we are in a learning phase with regards to the pathogenesis, disease manifestations, and therapeutics. In addition to the primary lung injury, many patients especially the ones with moderate to severe COVID-19 display evidence of endothelial damage, complement activation, which leads to a pro-coagulable state. While there are still missing links in our understanding, the interplay of endothelium, complement system activation, and immune response to the SARS-CoV-2 virus is a surprisingly major factor in COVID-19 pathogenesis. One could envision COVID-19 becoming a novel hematological syndrome. This review is to discuss the available literature with regards to the involvement of the complement system, and coagulation cascade and their interaction with endothelium.

    Search related documents:
    Co phrase search for related documents
    • abnormal coagulation and acute ards respiratory distress syndrome: 1, 2, 3, 4, 5
    • abnormal coagulation and low platelet: 1, 2
    • abnormal coagulation and lung injury: 1, 2, 3, 4, 5
    • activation adhesion and acute ards respiratory distress syndrome: 1
    • activation adhesion and adhesion molecule: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • activation adhesion and low platelet: 1, 2, 3
    • activation adhesion and lung injury: 1, 2, 3, 4, 5, 6, 7, 8
    • activation adhesion recruitment and acute ards respiratory distress syndrome: 1
    • activation adhesion recruitment and adhesion molecule: 1
    • activation adhesion recruitment and lung injury: 1
    • acute ards respiratory distress syndrome and adaptive immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute ards respiratory distress syndrome and adhesion molecule: 1, 2, 3, 4, 5, 6
    • acute ards respiratory distress syndrome and low platelet: 1, 2, 3
    • acute ards respiratory distress syndrome and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome patient and lung injury: 1, 2, 3, 4, 5, 6
    • adaptive immune response and adhesion molecule: 1, 2, 3
    • adaptive immune response and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • adhesion molecule and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • adhesion molecule and macular degeneration: 1